Virtually every cell in the human body has an internal clock. These clocks take their cues from a central clock in the brain. In a normal, biological process called synchrony, the central clock coordinates daily rhythms around ...
Dec 12, 2024
0
0
The Wistar Institute's David B. Weiner, Ph.D.—Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Smith Charitable Trust Distinguished Professor in Cancer Research—and his lab have successfully ...
Dec 3, 2024
0
1
Memorial Sloan Kettering Cancer Center-led researchers have identified a small molecule called gliocidin that kills glioblastoma cells without damaging healthy cells, potentially offering a new therapeutic avenue for this ...
A new study from scientists at the UCLA Health Jonsson Comprehensive Cancer Center helps explain why glioblastoma, one of the most aggressive forms of brain cancer, becomes resistant to treatment, and introduces a new approach ...
Nov 21, 2024
0
33
Even treated with the most advanced therapies, patients with glioblastoma—an aggressive brain cancer—typically survive less than two years after diagnosis. Efforts to treat this cancer with the latest immunotherapies ...
Nov 7, 2024
0
23
A research team at Lund University in Sweden has discovered a certain type of cell—foam cells—in patients with the aggressive brain tumor glioblastoma. It has been shown how these cells accelerate the cancer's growth ...
Nov 5, 2024
0
36
Glioblastoma is the most common and deadliest form of brain cancer. Patients face a bleak prognosis—the average survival after diagnosis is between 12 and 15 months. And just 6.9% of patients survive beyond five years, ...
Nov 4, 2024
0
0
A team led by researchers at the University of Toronto has uncovered new targets that could be the key to effectively treating glioblastoma, a lethal type of brain cancer. These targets were identified through a screen for ...
Nov 4, 2024
0
26
A team from The Institute of Cancer Research, London, has developed a new immuno-PET imaging technique that could spot which glioblastoma patients would respond well to immunotherapy and that tracks the response over time.
Oct 29, 2024
0
2
Glioblastomas are aggressive brain tumors with a median survival time of less than 22 months despite standard therapy including surgery, irradiation, and chemotherapy. It has become clear in recent years that not all cells ...
Oct 17, 2024
0
4
Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans, involving glial cells and accounting for 52% of all functional tissue brain tumor cases and 20% of all intracranial tumors. Despite being the most prevalent form of primary brain tumor, GBMs occur in only 2–3 cases per 100,000 people in Europe and North America. According to the WHO classification of the tumors of the central nervous system, the standard name for this brain tumor is "glioblastoma"; it presents two variants: giant cell glioblastoma and gliosarcoma. Glioblastomas are also an important brain tumor in canines, and research continues to use this as a model for developing treatments in humans.
Treatment can involve chemotherapy, radiation, radiosurgery, corticosteroids, antiangiogenic therapy, surgery and experimental approaches such as gene transfer.
With the exception of the brainstem gliomas, glioblastoma has the worst prognosis of any central nervous system (CNS) malignancy, despite multimodality treatment consisting of open craniotomy with surgical resection of as much of the tumor as possible, followed by concurrent or sequential chemoradiotherapy, antiangiogenic therapy with bevacizumab, gamma knife radiosurgery, and symptomatic management with corticosteroids. Prognosis is poor, with a median survival time of approximately 14 months.
This text uses material from Wikipedia licensed under CC BY-SA
